pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Aplenzin
drug
save

bupropion hydrobromide ER

Marketedupdated 3mo ago
by Bausch Health US LLC
Approved
community read0 votes

🐶 often sniffed alongside

top 3
  • tagApproval60 co-mentions · 15 sources
  • drugbupropion30 co-mentions · 15 sources
  • tagSmall Molecule30 co-mentions · 15 sources

indications

investigational
Major Depression

all catalysts(0)

nothing on the calendar yet

Trials studying bupropion hydrobromide ER

  • phase4Efficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With Major Depressive Disordernot yet recruitingn=246

Patent cliff

source: FDA Orange Book

patents (24)

  • Jun 27, 2026formulationUS 7241805
  • Jun 27, 2026formulationUS 7241805
  • Jun 27, 2026formulationUS 7241805
  • Jun 27, 2026method-of-use (U-997)US 7569610
  • Jun 27, 2026method-of-use (U-997)US 7569610
  • Jun 27, 2026method-of-use (U-997)US 7569610
  • Jun 27, 2026formulationUS 7572935
  • Jun 27, 2026formulationUS 7572935
  • Jun 27, 2026formulationUS 7572935
  • Jun 27, 2026formulationUS 7585897
  • Jun 27, 2026formulationUS 7585897
  • Jun 27, 2026formulationUS 7585897
  • Jun 27, 2026formulationUS 7645802
  • Jun 27, 2026formulationUS 7645802
  • Jun 27, 2026formulationUS 7645802
  • Jun 27, 2026formulationUS 7649019
  • Jun 27, 2026formulationUS 7649019
  • Jun 27, 2026formulationUS 7649019
  • Jun 27, 2026formulationUS 7662407
  • Jun 27, 2026formulationUS 7662407
  • Jun 27, 2026formulationUS 7662407
  • Jun 27, 2026formulationUS 7671094
  • Jun 27, 2026formulationUS 7671094
  • Jun 27, 2026formulationUS 7671094

News(0)

no news has mentioned this drug yet

brand
Aplenzin
generic
bupropion hydrobromide
indication
Major Depressive Disorder
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 45m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?